A Small-Molecule Triptolide Regulates Survival and Migration of Stromal Cells from Patients with Endometriosis

J. Li,X. Liang

DOI: https://doi.org/10.1016/j.fertnstert.2012.07.779

IF: 6.7

2012-01-01

Fertility and Sterility

Abstract:Endometriosis progresses with complicated molecular mechanisms and has the characteristics of sustained proliferation, anti-apoptosis and migration. The current therapies are insufficient due to the high cost and recurrence rate. We aim to estimate whether triptolide as a small, potent, easily produced compound, has a potential to be a candidate against severe endometriosis and to explore the potential signaling pathways. Experimental study. The eutopic endometrial tissues(n=10) were collected from patients with severe endometriosis. Meanwhile, the endometriotic tissues(n=5) were obtained undergoing laparoscopy. The stromal cells were isolated from eutopic and ectopic endometrial tissues and cultured. After various concentrations of triptolide treatments, the following techniques were employed to detect the survival and migration in vitro: BrdU incorporation assay for proliferation; Hoechest33258 stain and Caspase-3 activity for apoptosis; Wound healing assay for migrative ability; Western blotting for expressions of the key proteins in PI3K/Akt, JNK, and NF-kB pathways. Triptolide inhibited the proliferation of eutopic and ectopic endometrial stromal cells equally at extremely low concentration(10nmol/l) in 48h. And the proliferation inhibition rate was in a does-and time-dependent manners. For apoptosis, evident apoptotic cells characterized were observed in the endometrial and endometriotic cells after 50nmol/l triptolide treatment in 48h. Similarily, the small molecule was capable of inducing caspase-3 activation. Additionally, triptolide suppressed the migration of endometriotic stromal cells at 10 nmol/l in 48h. Furthermore, the endometriosis suppression occurred in concert with changes of key proteins expression belonged to PI3K/Akt, JNK, and NF-kB pathways. Our present data suggest triptolide as a novel and potent therapeutic agent could be an option in the management of severe endometriosis.